Objectives: Statins have significant therapeutic implications in patients having high cardiovascular risk or preexisting cardiovascular disorders. Exploring the correlation between statin therapy and outcomes in coronavirus disease 2019 (COVID-19) patients is the objective of the current meta-analysis. Data sources: PubMed, Web of Science, Google Scholar, and Cochrane Library database, as well as preprint services like medRxiv, Research Square, and Social Science Research Network (SSRN). Study selection: All citations will be double-checked, and any differences will be examined and, if required, addressed with the help of a third author. Two authors will separately evaluate abstracts and titles of all potentially essential citations in two phases. Data extraction: A data extraction table will be used to extract published outcomes from each study. Data synthesis: The pooled risk ratio with a 95% confidence interval (CI) will be used to compute pooled effect size. DerSimonian and Laird random-effects models will be employed for heterogeneity greater than 50%; otherwise, the fixed-effects model will be implemented. To construct study weights, an inverse variance approach will be employed, and a funnel plot will also be examined to see whether there is any publishing bias. Trial registry: International prospective register of systematic reviews (Prospero) acquired a prospective registration for this meta-analysis in the trial registry (CRD42022304331). Study highlights: The evidence supporting the use of statins in COVID-19 patients will be reviewed in this study. Early statin has been correlated to a decreased risk of unfavorable effects in patients with COVID-19. At the time, these trials were predominantly observational, and all published meta-analyses were based on observational studies. Randomized controlled trials have recently been performed for reliable evidence, but no meta-analyses.